nach oben

Erschienen in:

01.11.2010 | Case Report

Histiocytic sarcoma with two immunohistopathologically distinct populations

verfasst von: Kanako Wakahashi, Manabu Shimoyama, Yoshio Katayama, Kentaro Minagawa, Kenji Yoshida, Ryohei Sasaki, Shunji Nakayama, Hiroshi Yokozaki, Emmy Yanagita, Tomoo Itoh, Yoshitake Hayashi, Toshimitsu Matsui

Erschienen in: International Journal of Hematology | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

This report is a case of histiocytic sarcoma (HS), in which tumor cells consist of two immunohistopathologically distinct populations (A) oval CD68+lysozyme+CD163− cells and (B) abundant cytoplasm or spindle-shaped CD68+lysozyme−CD163+ cells. Cervical lymph node was infiltrated mainly by population (A), where chemotherapy was quite effective. On the other hand, vast majority of infiltrated tumor cells in the hilar lymph node belonged to population (B), in which the cells were resistant to chemo-radiotherapy. Considering the poor prognosis of HS, the expression of CD163 could be a marker for resistance to chemo-radiotherapy. It is also notable that CD163-negative stage of HS may exist and still be reactive for the treatment.

Rappaport H. Tumors of the hematopoietic system. Washington, DC: US Armed Forces Institute of Pathology; 1966.

Lau SK, Chu PG, Weiss LM. CD163: a specific marker of macrophages in paraffin-embedded tissue samples. Am J Clin Pathol. 2004;122:794–801.CrossRefPubMed

Vos JA, Abbondanzo SL, Barekman CL, Andriko JW, Miettinen M, Aguilera NS. Histiocytic sarcoma: a study of five cases including the histiocyte marker CD163. Mod Pathol. 2005;18:693–704.CrossRefPubMed

Pileri SA, Grogan TM, Harris NL, et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology. 2002;41:1–29.CrossRefPubMed

Mikami M, Sadahira Y, Suetsugu Y, Wada H, Sugihara T. Monocyte/macrophage-specific marker CD163+ histiocytic sarcoma: case report with clinical, morphologic, immunohistochemical, and molecular genetic studies. Int J Hematol. 2004;80:365–9.CrossRefPubMed

Yoshida C, Takeuchi M. Histiocytic sarcoma: identification of its histiocytic origin using immunohistochemistry. Intern Med. 2008;47:165–9.CrossRefPubMed

Huang SC, Chang CL, Huang CH, Chang CC. Histiocytic sarcoma—a case with evenly distributed multinucleated giant cells. Pathol Res Pract. 2007;203:683–9.CrossRefPubMed

Cao M, Eshoa C, Schultz C, Black J, Zu Y, Chang CC. Primary central nervous system histiocytic sarcoma with relapse to mediastinum: a case report and review of the literature. Arch Pathol Lab Med. 2007;131:301–5.PubMed

Abidi MH, Tove I, Ibrahim RB, Maria D, Peres E. Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant. Am J Hematol. 2007;82:932–3.CrossRefPubMed

10.

Alexiev BA, Sailey CJ, McClure SA, Ord RA, Zhao XF, Papadimitriou JC. Primary histiocytic sarcoma arising in the head and neck with predominant spindle cell component. Diagn Pathol. 2007;2:7.CrossRefPubMed

11.

Oka K, Nakamine H, Maeda K, et al. Primary histiocytic sarcoma of the spleen associated with hemophagocytosis. Int J Hematol. 2008;87:405–9.CrossRefPubMed

12.

Kobayashi S, Kimura F, Hama Y, et al. Histiocytic sarcoma of the spleen: case report of asymptomatic onset of thrombocytopenia and complex imaging features. Int J Hematol. 2008;87:83–7.CrossRefPubMed

13.

Feldman AL, Arber DA, Pittaluga S, et al. Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone. Blood. 2008;111:5433–9.CrossRefPubMed

14.

McClure R, Khoury J, Feldman A, Ketterling R. Clonal relationship between precursor B-cell acute lymphoblastic leukemia and histiocytic sarcoma: a case report and discussion in the context of similar cases. Leuk Res. 2009;34:e71–3.CrossRefPubMed

15.

Zhang D, McGuirk J, Ganguly S, Persons DL. Histiocytic/dendritic cell sarcoma arising from follicular lymphoma involving the bone: a case report and review of literature. Int J Hematol. 2009;89:529–32.CrossRefPubMed

16.

Shinoda H, Yoshida A, Teruya-Feldstein J. Malignant histiocytoses/disseminated histiocytic sarcoma with hemophagocytic syndrome in a patient with mediastinal germ cell tumor. Appl Immunohistochem Mol Morphol. 2009;17:338–44.CrossRefPubMed

17.

Yu L, Yang SJ. A case of primary histiocytic sarcoma arising from thyroid gland. Pathol Oncol Res. 2010;16:27–132.CrossRef

18.

Yang GC, Besanceney CE, Tam W. Histiocytic sarcoma with interdigitating dendritic cell differentiation: a case report with fine needle aspiration cytology and review of literature. Diagn Cytopathol. 2010;38:351–6.PubMed

19.

Venkataraman G, McClain KL, Pittaluga S, Rao VK, Jaffe ES. Development of disseminated histiocytic sarcoma in a patient with autoimmune lymphoproliferative syndrome and associated Rosai–Dorfman disease. Am J Surg Pathol. 2010;34:589–94.CrossRefPubMed

20.

Mori M, Matsushita A, Takiuchi Y, et al. Histiocytic sarcoma and underlying chronic myelomonocytic leukemia: a proposal for the developmental classification of histiocytic sarcoma. Int J Hematol. 2010;92:168–73.CrossRefPubMed

21.

deMent SH. Association between mediastinal germ cell tumors and hematologic malignancies: an update. Hum Pathol. 1990;21:699–703.CrossRefPubMed

22.

Ikdahl T, Josefsen D, Jakobsen E, Delabie J, Fossa SD. Concurrent mediastinal germ-cell tumour and haematological malignancy: case report and short review of literature. Acta Oncol. 2008;47:466–9.CrossRefPubMed

23.

Nishiwaki S, Terakura S, Ito M, et al. Impact of macrophage infiltration of skin lesions on survival after allogeneic stem cell transplantation: a clue to refractory graft-versus-host disease. Blood. 2009;114:3113–6.CrossRefPubMed

24.

Polfliet MM, Fabriek BO, Daniels WP, Dijkstra CD, van den Berg TK. The rat macrophage scavenger receptor CD163: expression, regulation and role in inflammatory mediator production. Immunobiology. 2006;211:419–25.CrossRefPubMed

25.

Hogger P, Dreier J, Droste A, Buck F, Sorg C. Identification of the integral membrane protein RM3/1 on human monocytes as a glucocorticoid-inducible member of the scavenger receptor cysteine-rich family (CD163). J Immunol. 1998;161:1883–90.PubMed

26.

Law SK, Micklem KJ, Shaw JM, et al. A new macrophage differentiation antigen which is a member of the scavenger receptor superfamily. Eur J Immunol. 1993;23:2320–5.CrossRefPubMed

27.

Kristiansen M, Graversen JH, Jacobsen C, et al. Identification of the haemoglobin scavenger receptor. Nature. 2001;409:198–201.CrossRefPubMed

28.

Fabriek BO, Dijkstra CD, van den Berg TK. The macrophage scavenger receptor CD163. Immunobiology. 2005;210:153–60.CrossRefPubMed

29.

Fabriek BO, van Bruggen R, Deng DM, et al. The macrophage scavenger receptor CD163 functions as an innate immune sensor for bacteria. Blood. 2009;113:887–92.CrossRefPubMed

30.

Schebesch C, Kodelja V, Muller C, et al. Alternatively activated macrophages actively inhibit proliferation of peripheral blood lymphocytes and CD4+ T cells in vitro. Immunology. 1997;92:478–86.CrossRefPubMed

31.

Hogger P, Sorg C. Soluble CD163 inhibits phorbol ester-induced lymphocyte proliferation. Biochem Biophys Res Commun. 2001;288:841–3.CrossRefPubMed

32.

Frings W, Dreier J, Sorg C. Only the soluble form of the scavenger receptor CD163 acts inhibitory on phorbol ester-activated T-lymphocytes, whereas membrane-bound protein has no effect. FEBS Lett. 2002;526:93–6.CrossRefPubMed

Titel: Histiocytic sarcoma with two immunohistopathologically distinct populations
verfasst von: Kanako Wakahashi
Manabu Shimoyama
Yoshio Katayama
Kentaro Minagawa
Kenji Yoshida
Ryohei Sasaki
Shunji Nakayama
Hiroshi Yokozaki
Emmy Yanagita
Tomoo Itoh
Yoshitake Hayashi
Toshimitsu Matsui
Publikationsdatum: 01.11.2010
Verlag: Springer Japan
Erschienen in: International Journal of Hematology / Ausgabe 4/2010
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-010-0699-1

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Histiocytic sarcoma with two immunohistopathologically distinct populations

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2010

Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia

Coexistence of chronic myeloid leukemia and pulmonary plasmacytoma mimicking primary lung cancer

Postremission gemtuzumab ozogamicin for elderly patients with acute myelogenous leukemia with favorable characteristics and comorbid conditions

Establishment of an HS23 stromal cell-dependent myeloma cell line: fibronectin and IL-6 are critical

Aggressive sporadic histiocytic sarcoma with immunoglobulin heavy chain gene rearrangement and t(14;18)

Successful salvage treatment of blastic natural killer cell lymphoma with methotrexate

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie